USP Discussion on RMMs and recommendations for USP Chapter 1223
The final session of this year’s PDA Global Conference on Pharmaceutical Microbiology is focused o…
The final session of this year’s PDA Global Conference on Pharmaceutical Microbiology is focused o…
Following the FDA presentations, Dr. Tsuguo Sasaki, Japanese PMDA, provided his views on the use of …
Follo wing comment from the Australian TGA, two FDA staff members provided their perspectives on RMM…
Yesterday, I reported on the Compendial RMM session where we heard from the chairs of the USP, Ph. E…
The Chairs of the USP, Ph. Eur. and JP provided their perspectives on the current and future state o…
Sara Polson, Accugenix, discussed their use of the Bruker MALDI time-of-flight mass spectrometry (TO…
Jennifer Gray of Novartis Pharma AG, Switzerland, presented their strategy for validating the Mill…
Dr. Tidswell presented an excellent overview of viable but non-culturable (VBNC) organisms and their…
Dr. David Hussong, FDA CDER, reviewed the impact that B. cepacia can have on pharmaceutical product …
Opening of the PDA Global Conference on Pharmaceutical Microbiology. Speaking is Dr. Mark Ott, Chie…
Remember to follow my live blog from the PDA Global Conference on Pharmaceutical Microbiology next w…
Madhu Raju Saghee, Tim Sandle and Ed Tidswell have recently published a new book entitled Microbiolo…
Rapid micro methods will be the talk of the town at the upcoming PDA Global Conference on Pharmaceut…
To address the microbiological needs of the global pharmaceutical and biotech industries, Quality Ac…
In the next few weeks I will be conducting an online survey on return on investment (ROI) and rapid …
A new publication from the September 2010 Journal of Microbiological Methods discusses the use of n…